Enanta Pharmaceuticals Management
Management criteria checks 2/4
Enanta Pharmaceuticals' CEO is Jay Luly, appointed in Jul 2003, has a tenure of 20.83 years. total yearly compensation is $7.86M, comprised of 9.6% salary and 90.4% bonuses, including company stock and options. directly owns 3.52% of the company’s shares, worth $10.22M. The average tenure of the management team and the board of directors is 3.4 years and 7.5 years respectively.
Key information
Jay Luly
Chief executive officer
US$7.9m
Total compensation
| CEO salary percentage | 9.6% |
| CEO tenure | 20.8yrs |
| CEO ownership | 3.5% |
| Management average tenure | 3.4yrs |
| Board average tenure | 7.5yrs |
Recent management updates
Recent updates
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Fly 27% But Investors Aren't Buying For Growth
Mar 05
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Feb 12Time To Worry? Analysts Are Downgrading Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Outlook
Aug 13We Discuss Why Enanta Pharmaceuticals, Inc.'s (NASDAQ:ENTA) CEO Compensation May Be Closely Reviewed
Feb 24Things Look Grim For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) After Today's Downgrade
Feb 08Downgrade: Here's How Analysts See Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Performing In The Near Term
Nov 25Is Enanta Pharmaceuticals (NASDAQ:ENTA) Weighed On By Its Debt Load?
Oct 25Enanta starts mid-stage trial of EDP-938 for RSV infection
Oct 03Enanta Pharma FQ3 2022 Earnings Preview
Aug 07Enanta potential COVID drug shows safety in healthy people in early-stage trial
Jul 29Enanta Pharmaceuticals (NASDAQ:ENTA) Has Debt But No Earnings; Should You Worry?
Jul 04Enanta: Slow Drip
May 17Time To Worry? Analysts Are Downgrading Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Outlook
Feb 04Is Enanta Pharmaceuticals (NASDAQ:ENTA) Using Debt In A Risky Way?
Nov 25Enanta Pharmaceuticals, Inc. 2021 Q1 - Results - Earnings Call Presentation
May 07Analysts Just Made A Noticeable Upgrade To Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Forecasts
Feb 11CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -US$138m |
| Sep 30 2023 | US$8m | US$755k | -US$134m |
| Jun 30 2023 | n/a | n/a | -US$132m |
| Mar 31 2023 | n/a | n/a | -US$125m |
| Dec 31 2022 | n/a | n/a | -US$121m |
| Sep 30 2022 | US$7m | US$725k | -US$122m |
| Jun 30 2022 | n/a | n/a | -US$120m |
| Mar 31 2022 | n/a | n/a | -US$112m |
| Dec 31 2021 | n/a | n/a | -US$101m |
| Sep 30 2021 | US$5m | US$693k | -US$79m |
| Jun 30 2021 | n/a | n/a | -US$84m |
| Mar 31 2021 | n/a | n/a | -US$74m |
| Dec 31 2020 | n/a | n/a | -US$58m |
| Sep 30 2020 | US$5m | US$667k | -US$36m |
| Jun 30 2020 | n/a | n/a | US$2m |
| Mar 31 2020 | n/a | n/a | US$24m |
| Dec 31 2019 | n/a | n/a | US$34m |
| Sep 30 2019 | US$4m | US$642k | US$46m |
| Jun 30 2019 | n/a | n/a | US$65m |
| Mar 31 2019 | n/a | n/a | US$78m |
| Dec 31 2018 | n/a | n/a | US$86m |
| Sep 30 2018 | US$4m | US$611k | US$72m |
| Jun 30 2018 | n/a | n/a | US$81m |
| Mar 31 2018 | n/a | n/a | US$52m |
| Dec 31 2017 | n/a | n/a | US$34m |
| Sep 30 2017 | US$4m | US$581k | US$18m |
Compensation vs Market: Jay's total compensation ($USD7.86M) is above average for companies of similar size in the US market ($USD1.64M).
Compensation vs Earnings: Jay's compensation has increased whilst the company is unprofitable.
CEO
Jay Luly (67 yo)
20.8yrs
Tenure
US$7,856,698
Compensation
Dr. Jay R. Luly, Ph.D. has been the Chief Executive Officer, President and Director of Enanta Pharmaceuticals, Inc. since July 2003. Dr. Luly joined Enanta in July 2003. Previously he was employed at Oxfor...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 20.8yrs | US$7.86m | 3.52% $ 10.2m | |
| Senior VP of Finance & Administration and CFO | 20.7yrs | US$2.85m | 0.35% $ 1.0m | |
| Senior VP of Research & Development and Chief Scientific Officer | 24.5yrs | US$2.97m | 1.66% $ 4.8m | |
| Consultant | less than a year | US$2.86m | 0.43% $ 1.2m | |
| Senior Vice President of Business Development | 3.3yrs | US$2.58m | 0.10% $ 299.6k | |
| Senior Director of Investor Relations & Corporate Communications | no data | no data | no data | |
| Senior Vice President of New Product Strategy & Development | 3.4yrs | US$2.10m | 0.11% $ 306.8k | |
| Senior VP & Chief Medical Officer | 1.8yrs | US$4.84m | 0.038% $ 110.4k |
3.4yrs
Average Tenure
67yo
Average Age
Experienced Management: ENTA's management team is considered experienced (3.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 20.8yrs | US$7.86m | 3.52% $ 10.2m | |
| Independent Director | 3.9yrs | US$331.41k | 0% $ 0 | |
| Independent Non-Executive Chairman | 10.5yrs | US$353.91k | 0% $ 0 | |
| Independent Director | 12.9yrs | US$333.91k | 0.027% $ 79.7k | |
| Independent Director | 6.7yrs | US$326.41k | 0% $ 0 | |
| Independent Director | 2.8yrs | US$318.91k | 0% $ 0 | |
| Independent Director | 7.5yrs | US$321.41k | 0% $ 0 |
7.5yrs
Average Tenure
64yo
Average Age
Experienced Board: ENTA's board of directors are considered experienced (7.5 years average tenure).